{"filings":[{"id":1609837,"accession_number":"0001048477-26-000011","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K/A","filed_at":"2026-07-13T20:06:29+00:00","items":["9.01"],"status":"ready","headline":"BioMarin provides Amicus audited 2025 financials; revenue $634M, net loss $27M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amicus 2025 net product sales $634.2M, up 20% YoY from $528.3M; net loss narrowed to $27.1M from $56.1M.","Amicus had $214.0M cash, $392.7M long-term debt, and $2.77B accumulated deficit as of Dec 31, 2025.","BioMarin acquired Amicus for $14.50/share in cash, closing April 27, 2026; this filing provides audited financials and pro forma.","Amicus revenue concentrated: one customer accounted for 24% of 2025 net product sales.","Pro forma condensed combined financials as of Dec 31, 2025 included in Exhibit 99.2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":861636,"accession_number":"0001628280-26-040812","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2026-06-04T20:24:22+00:00","items":["5.02","5.07"],"status":"ready","headline":"BioMarin shareholders approve 7.65M share increase in equity plan; all directors elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved adding 7,650,000 shares to the 2017 Equity Incentive Plan.","All ten director nominees were elected, including CEO Alexander Hardy.","KPMG LLP ratified as BioMarin's independent auditor for FY 2026.","Advisory say-on-pay proposal passed with 142.7M votes for and 21.3M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90879,"accession_number":"0001048477-26-000006","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioMarin Q1 revenue up 3% to $766M; EPS down; raises FY2026 guidance to $3.825-$3.925B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $766M (+3% YoY); GAAP net income $106M (down 43%) vs $186M.","GAAP diluted EPS $0.54 vs $0.95; non-GAAP diluted EPS $0.76 vs $1.13.","FY2026 revenue guidance raised to $3.825B-$3.925B, implying ~20% YoY growth at midpoint.","Operating cash flow $221M; closed $3.7B non-convertible debt to fund Amicus acquisition.","Enzyme Therapies revenue up 6% to $514M; VOXZOGO $220M (+3%); $31M charge for NAGLAZYME campaign."],"consensus_eps_estimate":null,"consensus_eps_actual":0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":766208000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90878,"accession_number":"0001193125-26-179243","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["1.01","2.03","2.01","7.01","9.01"],"status":"ready","headline":"BioMarin completes $4.8B acquisition of Amicus Therapeutics; adds Galafold, Pombiliti+Opfolda","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired Amicus for $14.50/share in cash; total equity value ~$4.8B.","Adds Galafold (Fabry), Pombiliti+Opfolda (Pompe) and DMX-200 (FSGS) to commercial portfolio.","Financed via $2.8B in new term loans ($2.0B Term B, $800M Term A) and 2034 notes.","Expects to provide updated FY2026 guidance on May 4 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90877,"accession_number":"0001193125-26-173770","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioMarin receives French FDI clearance for Amicus merger; closing expected April 27, 2026","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["French Ministry of Economics and Finance granted FDI clearance for merger with Amicus on April 23, 2026.","Receipt of clearance satisfies final condition to the merger other than closing conditions.","Merger expected to close on April 27, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100717,"accession_number":"0001193125-26-107314","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioMarin discontinues VOXZOGO trials in Turner, SHOX, ACAN after SCFE safety events","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinued dosing and enrollment in Phase 2 CANOPY trials for Turner syndrome, SHOX-deficiency, and ACAN-deficiency.","Decision follows slipped capital femoral epiphysis (SCFE) events in two investigator-sponsored trials; SCFE not seen in BioMarin's own trials or in >5,000 achondroplasia patients.","Phase 2 CANOPY trials for Noonan syndrome and idiopathic short stature (ISS) without ACAN-deficiency will continue as planned.","Over 10,000 patient-years of safety data in achondroplasia shows no SCFE cases; VOXZOGO remains approved for achondroplasia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100716,"accession_number":"0001048477-26-000002","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioMarin Q4 rev $875M (+17% Y/Y); GAAP net loss $47M on ROCTAVIAN withdrawal; Amicus deal on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenues $875M (+17% Y/Y); full-year $3.22B (+13% Y/Y).","Q4 GAAP net loss of $47M vs $125M income prior year; Non-GAAP income $89M vs $180M.","ROCTAVIAN withdrawal triggered ~$240M Q4 charges ($119M inventory write-off, $118M asset impairments).","VOXZOGO FY revenue $927M (+26% Y/Y); PALYNZIQ $433M (+22% Y/Y).","2026 guidance provided (ex-Amicus); Amicus acquisition expected to close in Q2'26."],"consensus_eps_estimate":null,"consensus_eps_actual":1.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":3221253000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100715,"accession_number":"0001193125-26-048736","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"BioMarin closes $850M 5.500% senior notes offering to fund Amicus acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Closed private placement of $850M 5.500% senior notes due 2034 at 100% issue price.","Net proceeds, combined with $2B term loan B, $800M term loan A, and cash, to fund Amicus acquisition.","Notes held in escrow; if acquisition not completed by Dec 19, 2026, notes redeemed at par plus accrued interest.","Notes guaranteed by certain subsidiaries; after closing, Amicus and its subsidiaries will also guarantee.","Expects to enter $600M senior secured revolving credit facility in connection with the acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100714,"accession_number":"0001193125-26-029401","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioMarin prices $850M 5.500% notes due 2034 and syndicates $2B term loan for Amicus acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$850M 5.500% senior notes due 2034; price 100%; expected close Feb 12, 2026.","Syndicated $2B term loan B, plus $800M term loan A and $600M revolver for pending Amicus acquisition.","Proceeds from notes and term loans, plus cash on hand, to fund Amicus acquisition consideration and fees.","If acquisition not completed by Dec 19, 2026, notes subject to special mandatory redemption at 100% plus accrued interest.","Notes guaranteed by BioMarin subsidiaries including Amicus post-closing; covenants limit debt, dividends, liens."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100713,"accession_number":"0001193125-26-021718","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"BioMarin guides ~$3.2B FY2025 revenue; plans $850M notes + $2.8B loans for Amicus deal","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["FY2025 preliminary total revenue ~$3.2B, including ~$920M from VOXZOGO; cash & investments ~$2.1B.","Launches $850M senior notes due 2034 and $2.8B in term loans ($2B Term Loan B + $800M Term Loan A) plus $600M revolver.","Proceeds escrowed; notes due Dec 2034 subject to special mandatory redemption at 100% if Amicus acquisition fails to close by Dec 19, 2026.","Acquisition of Amicus expected to close in Q2 2026, subject to Amicus stockholder vote and antitrust clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100712,"accession_number":"0001193125-26-010508","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioMarin estimates FY2025 revenue ~$3.2B; expects $230-260M ROCTAVIAN asset write-down","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary FY2025 total revenue ~$3.2B, with VOXZOGO contributing ~$920M.","ROCTAVIAN asset write-down of ~$230-260M in Q4 2025; $0.60-$0.64 non-GAAP EPS impact.","Excluding write-down, previous FY2025 non-GAAP EPS guidance unchanged.","Approximately 200M weighted-average diluted shares outstanding assumed."],"consensus_eps_estimate":null,"consensus_eps_actual":1.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":3221253000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117014,"accession_number":"0001193125-25-327828","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"BioMarin ends development of oral AATD liver disease candidate BMN 349","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinued BMN 349, an oral therapeutic for alpha-1 antitrypsin deficiency (AATD)-associated liver disease.","Decision announced on December 19, 2025; no reason for discontinuation disclosed.","No financial impact or pipeline replacement details provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117013,"accession_number":"0001193125-25-325856","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"BioMarin to acquire Amicus Therapeutics for $4.8B in all-cash deal at $14.50/share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["BioMarin acquires Amicus for $14.50/share in cash, total equity value ~$4.8B; expected Q2 2026 close.","Acquisition adds Galafold (Fabry) and Pombiliti+Opfolda (Pompe) products; Amicus's trailing 12-month revenue $599M.","BioMarin secures up to $3.65B bridge loan from Morgan Stanley to fund transaction.","Deal expected to be accretive to Non-GAAP diluted EPS in first 12 months post-close, substantially accretive from 2027.","Amicus board unanimously recommends; subject to Amicus stockholder approval and regulatory clearances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117012,"accession_number":"0001193125-25-322704","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioMarin appoints Rashmi Ramchandani as Chief Accounting Officer, effective Jan 19, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ramchandani becomes VP, Chief Accounting Officer and principal accounting officer; CFO Brian Mueller remains principal financial officer.","Compensation: $460k base salary, $400k sign-on bonus, 45% target bonus, RSUs valued at $1.05M (4-year vest) and $400k (1-year cliff), options valued at $450k (4-year monthly vest).","She previously served as VP, Global Business Controller at Gilead Sciences and VP, Controller at Strava. Background includes Deloitte, Clorox, McKesson.","Sign-on bonus repayable if employment ends within two years for reasons other than job elimination, death, or disability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117011,"accession_number":"0001048477-25-000104","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioMarin Q3 net loss $31M vs income $106M YoY; revenue +4% to $776M; guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss of $31M (diluted EPS -$0.16) vs income $106M ($0.55) in Q3 2024, due to $221M IPR&D charge from Inozyme acquisition.","Non-GAAP income fell to $22M ($0.12 EPS) from $178M ($0.91), reflecting the Inozyme charge and SG&A investments.","Total revenue $776M (+4% YoY); VOXZOGO $218M (+15%), PALYNZIQ $109M (+20%), but ALDURAZYME -24% and NAGLAZYME -8%.","Full-year 2025 total revenue guidance raised at midpoint; VOXZOGO outlook reaffirmed at $900M-$935M.","Company pursuing options to divest ROCTAVIAN (hemophilia A gene therapy), including out-licensing."],"consensus_eps_estimate":null,"consensus_eps_actual":2.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":2346688000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117010,"accession_number":"0001048477-25-000101","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"BioMarin expects $221M IPR&D charge from Inozyme acquisition, ~$1.10 EPS hit in Q3 2025","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Acquired IPR&D charge of ~$221M pre-tax from July 1 Inozyme Pharma acquisition.","Charge reduces both GAAP and Non-GAAP diluted EPS by approximately $1.10 for Q3 2025.","Q3 2025 results not finalized; actual results may differ from preliminary estimates.","BioMarin does not forecast IPR&D charges due to uncertainty of timing and magnitude."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133450,"accession_number":"0001048477-25-000098","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioMarin Chief Accounting Officer Erin Burkhart resigns; CFO to serve as interim principal accounting officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erin Burkhart notified her resignation as Chief Accounting Officer, effective September 2, 2025; departure is voluntary with no disagreement.","BioMarin will conduct a search for a successor; if none is appointed by the Effective Date, CFO Brian Mueller will serve as principal accounting officer.","Mueller will remain Executive VP and CFO with no additional compensation or adjustments for assuming the principal accounting officer duties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133449,"accession_number":"0001048477-25-000088","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioMarin Q2 revenue $825M (+16% Y/Y); GAAP EPS $1.23 (+124%); raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $825M, +16% Y/Y; GAAP net income $241M (vs $107M) and diluted EPS $1.23 (+124%).","Non-GAAP diluted EPS $1.44 (+50%); N-GAAP operating margin 39.9% (up 8.7pp Y/Y).","VOXZOGO revenue $221M (+20%) and Enzyme Therapies $555M (+15%); KUVAN down 7% to $27M.","Raised FY2025 guidance for total revenues, non-GAAP operating margin, and non-GAAP diluted EPS.","Completed Inozyme acquisition (July); BMN 333 (achondroplasia) Phase 2/3 to start 1H'26; BMN 390 discontinued."],"consensus_eps_estimate":null,"consensus_eps_actual":2.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":1570555000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133448,"accession_number":"0001048477-25-000086","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioMarin appoints Ian T. Clark to Board of Directors effective August 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased from ten to eleven members to accommodate Clark's appointment.","Clark appointed to Audit Committee and Science and Technology Committee.","Received RSU grant valued at $400,000 under 2017 Equity Incentive Plan.","Will receive standard non-employee director fees and committee retainers as outlined in proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150131,"accession_number":"0001193125-25-125040","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"BioMarin shareholders approve 8M share increase in equity plan, re-elect all directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved 8M additional shares under the 2017 Equity Incentive Plan (157.3M for, 7.7M against).","All ten director nominees, including Elizabeth Anderson and Alexander Hardy, re-elected.","KPMG ratified as independent auditor for FY2025 with 168.6M votes in favor.","Advisory vote on executive compensation passed with over 93% support of votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150130,"accession_number":"0001193125-25-121296","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"BioMarin acquires Inozyme for $4.00/share (~$270M cash); adds late-stage ENPP1 therapy","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All-cash tender offer at $4.00 per share; total equity value ~$270M; expected to close Q3 2025.","INOZYME's lead asset INZ-701 is a Phase 3 enzyme replacement for ENPP1 Deficiency; first pivotal data in children expected early 2026.","Inozyme Board unanimously recommends; stockholders representing ~11.2% of shares have entered support agreements.","BioMarin reaffirms FY2025 guidance and plan to achieve 40% Non-GAAP Operating Margin in 2026.","Transaction not subject to financing condition; Goldman Sachs advised BioMarin, Centerview advised Inozyme."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150129,"accession_number":"0001048477-25-000049","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioMarin Q1 2025 revenue $745M (+15% YoY), GAAP EPS $0.95, reaffirms 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenues $745M (+15% Y/Y); GAAP net income $186M (+109% Y/Y); non-GAAP income $221M (+58% Y/Y).","VOXZOGO revenue $214M (+40% Y/Y) driven by global demand; Enzyme Therapies revenue $484M (+8% Y/Y) led by PALYNZIQ (+22% Y/Y).","GAAP diluted EPS $0.95 (+107% Y/Y); non-GAAP diluted EPS $1.13 (+59% Y/Y). Operating margin expanded 16.4 ppt GAAP, 11.9 ppt non-GAAP.","Reaffirmed full-year 2025 financial guidance; notes immaterial tariff exposure from enacted tariffs.","Pipeline: VOXZOGO pivotal hypochondroplasia study fully enrolled; BMN 333 plan agreed with FDA; PALYNZIQ adolescent study met primary endpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":745145000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169131,"accession_number":"0001193125-25-044103","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"BioMarin amends bylaws to adopt majority voting for directors and tighten advance notice provisions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Uncontested director elections now require 'for' votes to exceed 'against' votes (majority voting standard).","Advance notice deadlines clarified; stockholder must appear at meeting or proposal is disregarded.","Stockholders must update disclosure information as of record date and 10 days before meeting.","Company may request information on nominee independence; substitute nominees require full disclosure.","Officers may be removed by majority of directors present at a meeting with a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169130,"accession_number":"0001193125-25-033463","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioMarin appoints Timothy Walbert to board, expanding size to 12 members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 11 to 12 members; Walbert appointed effective February 24, 2025.","Walbert receives standard independent director compensation including pro rata RSU grant (annual award $400,000).","No committee assignments at this time; standard indemnification agreement to be entered into."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169129,"accession_number":"0001048477-25-000004","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioMarin reports Q4 revenue $747M (+16%), full-year GAAP EPS $2.21, guides 2025 rev growth ~10%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $747M (+16% YoY); full-year $2.854B (+18%). GAAP diluted EPS $0.64 (Q4) and $2.21 (FY), up 154% YoY.","Non-GAAP diluted EPS $0.92 (Q4) and $3.52 (FY), up 69% YoY. Non-GAAP operating margin 28.6% for FY, up 9.2 ppts.","VOXZOGO revenue $208M in Q4 (+42%), $735M full-year (+56%); on track for >25% CAGR 2023-2027.","FY 2025 guidance: total revenue growth ~10% at midpoint; non-GAAP diluted EPS growth ~22%; targeting $4B revenue by 2027.","Pipeline: BMN 333 (CNP) first-in-human dosed, BMN 351 DMD data H2 2025; PALYNZIQ adolescent study data mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":2.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":2853915000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186191,"accession_number":"0001048477-24-000149","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioMarin Q3 revenue $746M (+28% YoY), GAAP EPS $0.55 (+162%), raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $746M (+28% YoY); VOXZOGO revenue +54% YoY; enzyme therapies +27%.","GAAP diluted EPS $0.55 (+162%); Non-GAAP diluted EPS $0.91 (+98%).","Raised full-year 2024 guidance for total revenue, Non-GAAP operating margin, and Non-GAAP EPS.","Retired $495M convertible debt in cash, eliminating ~4M dilutive shares.","Over 3,800 children on VOXZOGO; majority of US new starts under age 5."],"consensus_eps_estimate":null,"consensus_eps_actual":1.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":2106602000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202822,"accession_number":"0001193125-24-224139","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2024-09-24T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"BioMarin reaffirms long-term guidance: ~$4B revenue by 2027, 40% margin from 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reaffirms ~$4B total revenues in 2027.","Non-GAAP operating margin of 40% starting in 2026, growing to low- to mid-40% range.","Targets >$1.25B operating cash flow per year starting in 2027.","Mid-teen CAGR for total revenues through 2034.","Potential treatments for skeletal conditions represent >$5B revenue opportunity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202821,"accession_number":"0001048477-24-000136","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"BioMarin enters $600M revolving credit facility maturing 2029, undrawn at closing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered $600M revolving credit facility with Citibank as administrative agent.","Facility matures on August 28, 2029; no amounts drawn at closing.","Interest: Term SOFR plus 112.5-175 bps or Base Rate plus 12.5-75 bps, based on leverage.","Proceeds to finance working capital and general corporate purposes.","Includes customary covenants restricting debt, liens, investments, and dividends."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202820,"accession_number":"0001048477-24-000132","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"BioMarin to cut ~225 jobs, incur $30-35M in severance costs by end of 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~225 employees committed on Aug 23, 2024, in organizational redesign.","Estimated pre-tax charges of $30-35M for severance and termination benefits, mostly in H2 2024.","Plan follows updated ROCTAVIAN strategy and discontinuation of BMN 293 development announced Aug 5, 2024.","Notifications completed by Aug 28, 2024; reductions expected substantially complete by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202819,"accession_number":"0001193125-24-205405","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2024-08-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioMarin R&D chief Henry Fuchs to retire March 2025; Greg Friberg to succeed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Henry J. Fuchs to retire from BioMarin effective March 3, 2025.","Dr. Greg Friberg to assume EVP, Chief Worldwide R&D Officer role on September 30, 2024.","Fuchs will serve as senior advisor from October 1, 2024 until retirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202818,"accession_number":"0001048477-24-000125","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioMarin Q2 revenue $712M (+20% YoY), GAAP EPS $0.55 (+90%), raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["VOXZOGO revenue $183.9M (+62% YoY); ~3,500 children on treatment across 44 countries.","GAAP net income $107.2M (+91% YoY); Non-GAAP EPS $0.96 (+78% YoY) vs $0.54.","FY2024 guidance raised: total revenue, Non-GAAP operating margin, Non-GAAP EPS all increased.","ROCTAVIAN restructuring: focus on US, Germany, Italy; target $60M annual expenses by 2025; Q2 rev $7M.","Discontinued BMN 293 (gene therapy for hypertrophic cardiomyopathy); BMN 351/349/333 on track."],"consensus_eps_estimate":null,"consensus_eps_actual":1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":1360862000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218999,"accession_number":"0001193125-24-147013","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioMarin shareholders elect all director nominees, ratify KPMG, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected; highest vote count 152.1M for Barbara Bodem, lowest 143.7M for Elizabeth Anderson.","Ratification of KPMG as independent auditor for FY2024 passed with 156.5M for, 6.4M against.","Advisory vote on executive compensation approved with 141.9M for, 10.8M against.","Approximately 162.99M shares voted out of 189.78M entitled as of March 25, 2024 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218998,"accession_number":"0001048477-24-000082","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"BioMarin to cut ~170 jobs, book $15-20M charge from R&D program exits","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Strategic portfolio assessment led to discontinuation of certain R&D programs.","Workforce reduction of approximately 170 employees; majority notified May 14, 2024.","Estimated $15-20M pre-tax charges in Q2 2024 for severance and termination benefits.","Workforce reductions expected to be substantially completed by end of July 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218997,"accession_number":"0001048477-24-000066","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2024-04-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioMarin Q1 revenue $649M (+9% YoY); raises non-GAAP EPS and margin guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.46 (+70% YoY); Non-GAAP diluted EPS $0.71 (+18% YoY).","VOXZOGO revenue $153M (+74% YoY); over 3,100 children treated (+102% YoY).","Full-year 2024 total revenue reaffirmed; non-GAAP margin and EPS guidance raised on $35-40M net OpEx savings.","R&D portfolio prioritized: accelerated BMN 333, BMN 349, BMN 351; discontinued BMN 331, 255, 355, 365."],"consensus_eps_estimate":null,"consensus_eps_actual":0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":648833000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218996,"accession_number":"0001193125-24-107015","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioMarin settles derivative suits; governance reforms and up to $1.25M fee cap","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement resolves Wang v. Bienaimé and Tsantes v. Bienaimé derivative actions in Delaware Chancery Court.","BioMarin to implement corporate governance reforms (Exhibit A) for at least four years.","BioMarin will not oppose plaintiffs' counsel fee award not to exceed $1.25 million.","No admission of wrongdoing; defendants continue to deny all claims.","Settlement is subject to final approval by the Delaware Court of Chancery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238889,"accession_number":"0001048477-24-000013","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioMarin reports record FY2023 revenue $2.42B (+15% YoY); non-GAAP EPS $2.08 (+36% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 total revenues $2.42B (+15% YoY); GAAP diluted EPS $0.87 (+16% YoY); non-GAAP diluted EPS $2.08 (+36% YoY).","VOXZOGO net revenues $146M in Q4'23 (+118% Q/Q) and $470M for FY'23 (+178% YoY); 2,613 children treated at year-end.","Q4'23 total revenues $646.2M (+20% YoY); GAAP net income $20.4M vs $0.2M loss in Q4'22.","2024 guidance: double-digit total revenue growth, non-GAAP operating margin expansion, EPS growing faster than revenue.","FDA approved VOXZOGO for children under 5; ~70% of new US starts from that age group in Q4'23."],"consensus_eps_estimate":null,"consensus_eps_actual":0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":2419226000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238888,"accession_number":"0001193125-24-006599","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2024-01-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioMarin CCO Jeffrey Ajer to step down effective July 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey Ajer, EVP and Chief Commercial Officer, will depart on July 1, 2024.","No successor named; compensation unchanged until departure date.","Separation treated as without-cause termination; Ajer eligible for severance per employment agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256371,"accession_number":"0001193125-23-300042","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"BioMarin settles with Elliott; appoints 3 new directors, forms strategic review committee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board expanded to 15 directors; appoints Barbara Bodem, Athena Countouriotis, Mark Enyedy as independent directors effective Dec 27, 2023.","New Strategic and Operating Review Committee chaired by Richard Meier; includes CEO Alexander Hardy and Maykin Ho; to review business, strategy, and capital allocation.","Cooperation agreement with Elliott includes standstill, voting commitments, and mutual non-disparagement; Elliott supports the changes.","Company commits to holding an investor day in 2024 after committee recommendations; Elliott entered into information-sharing agreement for JPM conference and earnings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256370,"accession_number":"0001193125-23-270370","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BioMarin CEO Jean-Jacques Bienaimé retiring; Alexander Hardy appointed new CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jean-Jacques Bienaimé retires as President, CEO and Chairman on Nov 30, 2023; remains on board until 2024 annual meeting.","Alexander Hardy (ex-Genentech CEO) becomes President and CEO and joins board effective Dec 1, 2023.","Hardy receives $1,050,000 annual base salary, $900,000 signing bonus, and ~$15.5M in equity grants with multi-year vesting.","Bienaimé eligible for 2023 bonus at 120% of base salary if he remains director/consultant; consulting pays $146k/mo then $73k/mo.","Lead independent director Richard A. Meier becomes Board Chair effective Dec 1, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256369,"accession_number":"0001048477-23-000041","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioMarin Q3 2023: revenue $581M (+15% YoY), VOXZOGO $123M (+155%), cuts ROCTAVIAN guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $581.3M (+15% YoY), GAAP net income $40.4M vs loss $6.7M, GAAP diluted EPS $0.21 vs ($0.04).","VOXZOGO revenue $123.1M (+155% YoY); full-year guidance raised to $435-455M from $400-440M.","ROCTAVIAN revenue $0.8M; full-year guidance slashed to <$10M from $50-150M due to pricing delays.","Full-year 2023 total revenue guidance narrowed to $2.39-2.47B; Non-GAAP diluted EPS guided $1.90-2.05.","Management expects 2024 revenue to approach $3B; VOXZOGO age expansions in US and EU; hypochondroplasia trial to start."],"consensus_eps_estimate":null,"consensus_eps_actual":0.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":1773019000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273776,"accession_number":"0001048477-23-000026","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2023-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioMarin Q2 revenues $595M (+12% YoY), raises FY VOXZOGO guidance to $400-440M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenues $595.3M (+12% YoY); GAAP net income $56.0M ($0.29 diluted EPS); Non-GAAP income $105.2M ($0.54 diluted EPS).","Record H1 2023 revenues of $1.19B (+13% YoY); VOXZOGO Q2 sales surged 229% to $113.3M.","Full-year VOXZOGO revenue guidance raised to $400-440M (was $380-430M); GAAP net income guidance raised to $165-215M.","US approved ROCTAVIAN on June 29; commercial launch started; European reimbursement negotiations continue.","Pivotal program for VOXZOGO in hypochondroplasia to begin in Q4 2023; ongoing studies for age expansion and pipeline updates."],"consensus_eps_estimate":null,"consensus_eps_actual":0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":1191690000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290843,"accession_number":"0001193125-23-156584","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2023-05-30T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"BioMarin stockholders approve 14M share increase to equity plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected all 11 director nominees; each received substantial majority support.","Advisory vote on named executive officer compensation passed with 129.8M for, 24.5M against.","Amendment to 2017 Equity Incentive Plan adding 14M shares approved by shareholders.","KPMG LLP ratified as independent auditor for fiscal 2023; advisory vote on compensation frequency set to 1 year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290842,"accession_number":"0001048477-23-000016","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2023-04-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioMarin Q1 revenue $596.4M (+15% YoY); VOXZOGO guidance raised to $380-$430M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.27 (down from $0.63 due to $89M prior-year PRV gain); Non-GAAP EPS $0.60 (up from $0.52).","VOXZOGO Q1 revenue $87.8M (+346% YoY); full-year guidance raised from $330-$380M to $380-$430M, driven by Japan and Brazil.","ROCTAVIAN full-year revenue guidance lowered to $50-$150M (from $100-$200M) due to Germany reimbursement shift and U.S. PDUFA delay to June 30, 2023.","Enzyme product revenues $448.1M (+5% YoY); ALDURAZYME up 41% on timing of orders to Sanofi.","Total cash & investments $1,492.7M; full-year revenue guidance unchanged at $2.375-$2.5B, with GAAP net income $155-$205M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":596415000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311696,"accession_number":"0001048477-23-000005","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioMarin reports record Q4 revenues $537.5M (+19% YoY); guides 2023 total rev $2.375-2.5B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenues $537.5M, up 19% YoY; full year $2.096B, up 14%.","GAAP net loss improved to $0.2M in Q4 from $57.9M loss; full year net income $141.6M.","VOXZOGO full year revenues $169.1M, up from $5.9M in 2021; 1,264 children treated as of Jan 2023.","2023 guidance: total rev $2.375-2.5B, GAAP net income $155-205M, non-GAAP EPS $1.80-2.05.","ROCTAVIAN 2023 revenue guidance $100-200M; FDA PDUFA date March 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":2096039000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311695,"accession_number":"0001193125-23-006489","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2023-01-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioMarin estimates FY2022 total revenue of $2.09B, VOXZOGO sales $169M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited total revenue for FY2022 estimated at $2.09 billion.","VOXZOGO contributed approximately $169 million in revenue for FY2022.","Revenue figures are preliminary and subject to completion of quarterly closing procedures.","Full FY2022 results expected to be reported in February 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":2096039000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330263,"accession_number":"0001193125-22-310054","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2022-12-21T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"BioMarin adopts amended bylaws with DGCL alignment and universal proxy rule updates","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amended bylaws effective Dec 15, 2022, updating notice and meeting adjournment to align with DGCL.","Requires stockholders soliciting proxies to use a proxy card color other than white.","Amends procedural mechanics for stockholder nominations and proposals under SEC Rule 14a-19 (Universal Proxy Rules).","Includes administrative, modernizing, and clarifying changes to the bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330262,"accession_number":"0001048477-22-000030","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2022-10-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioMarin Q3 revenue up 24% YoY to $505M; VOXZOGO guidance raised to $140-170M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $505.3M (+24% YoY); GAAP net loss narrowed to $6.7M from $36.5M; Non-GAAP income $82.7M.","VOXZOGO net product revenue $48.3M, with 713 children treated; full-year guidance raised to $140-170M.","ROCTAVIAN BLA accepted by FDA, PDUFA March 31, 2023; EU commercial launch underway after August 2022 approval.","KUVAN revenue fell 16% QoQ and 20% YTD due to U.S. generic competition, as expected.","Full-year total revenue guidance reaffirmed at $2.06-2.16B; R&D and SG&A guidance ranges revised modestly."],"consensus_eps_estimate":null,"consensus_eps_actual":0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":1558501000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330261,"accession_number":"0001193125-22-259009","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2022-10-07T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"BioMarin cuts ~120 jobs, expects $50M annual savings to reinvest","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~120 employees; pre-tax charges of $20-25M in Q3/Q4 2022.","Expected annualized cost savings ~$50M; savings to be reinvested in operations to boost profitability.","Majority of reductions announced Oct 6, 2022; substantially complete by Dec 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347822,"accession_number":"0001193125-22-242460","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2022-09-12T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"BioMarin reports phase 3 BMN 270 patient diagnosed with leukemia; initial tests find no link to therapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BMN 270 phase 3 participant diagnosed with B-ALL; 85% of leukemic cells had Ph-like translocation.","BMN 270 vector DNA in leukemic cells was negligible (<1 copy per 500 cells), suggesting no clonal expansion.","No trial hold; all BMN 270 studies continue enrollment; DSMB agreed no modification needed.","BioMarin remains on track to resubmit BMN 270 BLA to FDA by end of September 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347821,"accession_number":"0001048477-22-000025","cik":1048477,"company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BioMarin reports record Q2 revenues of $534M; raises FY2022 guidance on Voxzogo growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $533.8M (+6% YoY); GAAP net income $27.7M vs $12.9M in Q2 2021.","Voxzogo contributed $34.4M (first full quarter of U.S./EU sales); 446 children treated globally as of June 30.","FY2022 total revenue guidance raised to $2.06-2.16B; Voxzogo net product revenue guidance raised to $130-160M.","Expects EC approval of Roctavian for hemophilia A in Q3; BLA resubmission in U.S. planned for September 2022.","Kuvan revenues declined 27% YoY to $57.6M due to generic competition; total revenues growth excluding Kuvan was 13% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":1053157000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":10124239123.507942,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-03T23:59:59+00:00|347821"}